NCT03071042

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Sir Run Run Shaw Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).

Conditions

• Metastatic Gastric Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
DRUG	Docetaxel	Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib

Timeline

• Start date: 2015-10-01
• Primary completion: 2017-12-01
• Completion: 2018-06-01
• First posted: 2017-03-06
• Last updated: 2017-03-06

Locations

1 site across 1 country: China